Repare Therapeutics Announces US$82.5 Million Series B Financing

肿瘤精确疗法公司Repare Therapeutics获8250万美元B轮融资

2019-09-06 11:30:00 BioSpace

本文共1162个字,阅读需3分钟

Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced today the completion of a US$82.5 million Series B financing. Cowen Healthcare Investments led the financing and was joined by new investors OrbiMed, Redmile, BVF Partners L.P. and Logos Capital. Founding investor Versant Ventures and existing investors MPM Capital, Fonds de solidarité FTQ, and BDC Capital all participated. Including today’s Series B financing and the June 2017 Series A round co-led by Versant and MPM, Repare has now secured over US$140 million in equity and partner capital. “We are pleased to include this exceptional group of new investors along with our strong existing group of shareholders to continue building Repare’s leading position in synthetic lethality and DNA damage repair precision oncology treatments,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. The core concept of synthetic lethality is that while tumors can tolerate individual defects in DNA, there are combinations of defects that create unique vulnerabilities in cancer cells which, when identified, present opportunities for precisely targeted therapeutics. Repare will use the proceeds of this financing to advance RP-3500, an ATR inhibitor, into the clinic in 2020. Repare will also advance an additional program, “Manchester”, an undisclosed CCNE1 synthetic lethal targeted therapy, in the subsequent two to three quarters, and will continue to progress its deep pipeline of synthetic lethal, DNA damage repair programs, including its Polθ program, which was recently partnered with ONO Pharmaceutical Co., Ltd. in Japan and selected territories in Asia. In connection with this investment, Kevin Raidy, Managing Partner, Cowen Healthcare Investments, and David Bonita, M.D., Partner, OrbiMed, will join Repare’s Board of Directors. “We are confident in Repare’s exceptional management team and are excited by the potential of the company’s lead asset and innovative pipeline to advance treatments for targeted patient populations in multiple cancer indications,” said Mr. Raidy. “We feel that Repare is differentiated and highly enabled. Synthetic lethality and DNA damage repair remain critical domains for novel precision oncology and we believe that Repare has established itself as the leader in this field,” noted Dr. Bonita. About Repare Therapeutics Repare Therapeutics is pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations. The company’s initial focus is on novel targeted therapies in cancer types harboring defective DNA-damage response (DDR)- or genome instability-related functions. Repare’s SNIPRx™ platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery technology with high‐resolution protein crystallography, computational biology, medicinal chemistry and clinical informatics to rapidly generate small molecules for clinical investigation.
一家精确的肿瘤治疗公司,针对基因定义的患者群体中肿瘤的特定脆弱性,今天宣布完成8250万美元的 B 系列融资。Cowen Healthcare Investments 负责融资,新投资者 OrbiMed 、 Red英里、 BVF Partners L.P .和 Logos Capital 也参与了融资。创始投资者 Versant Ventures 和现有投资者 MPM Capital 、 Fonds de solidarit é FTQ 和 BDC Capital 均参与了此次活动。 包括今天的 B 系列融资和2017年6月由 Versant 和 MPM 共同领导的 A 系列融资, Repare 现在已获得超过1.4亿美元的股权和合伙人资本。 “我们很高兴包括这一特殊的新投资者群体,以及我们强大的现有股东群体,继续在合成致死性和 DNA 损伤修复精准肿瘤治疗方面保持领先地位,” Repire 总裁兼首席执行官劳埃德· M ·西格尔( Lloyd M . Segal )说。 合成致死性的核心概念是,虽然肿瘤可以容忍 DNA 中的个体缺陷,但也存在着一些缺陷的组合,这些缺陷会在肿瘤细胞中产生独特的脆弱性,一旦被发现,就会为精确靶向治疗提供机会。修复将利用本次融资募集资金于2020年将 ATR 抑制剂 RP-3500提前投入临床。在随后的两到三个季度中,修理部还将推进一项名为“曼彻斯特”的补充计划,这是一项未公开的 CCNE1合成致命靶向治疗,并将继续推进其合成致命 DNA 损伤修复计划的深入进程,包括最近与 ONO 制药公司合作的 Polθ计划。日本及亚洲部分地区的有限公司。 与本次投资相关, Cowen Healthcare Investments 执行合伙人 Kevin Raidy 和 OrbiMed 合伙人 David Bonita 医学博士(M.D.)博士将加入 Repare 董事会。 “我们对 Repare 的卓越管理团队充满信心,并对该公司的领先资产和创新管道的潜力感到兴奋,该管道有望推进针对多个癌症适应症的目标患者人群的治疗,” Raidy 先生说。 “我们觉得维修是有区别的,并且非常有效。合成致死性和 DNA 损伤修复仍然是新的精确肿瘤学的关键领域,我们相信修复已经成为该领域的领导者。” 关于修复疗法 修复治疗是合成致死性的先驱,以开发新的治疗方法,针对特定的肿瘤在基因定义的患者群体。该公司最初的重点是新的靶向治疗癌症类型含有缺陷的 DNA 损伤反应( DDR )-或基因组不稳定相关功能。Repare 的 SNIPRx ™平台结合了专有、高通量、 CRISPR 支持的基因编辑目标发现技术和高分辨率蛋白质晶体学、计算生物学、药物化学和临床信息学,快速生成小分子用于临床研究。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文